Dermatology Diagnostics and Therapeutics Market to achieve USD 22.5 Billion by 2020 Owing

According to a market research report published by iHealthcareAnalyst, Inc., Dermatology Diagnostics and Therapeutics Market – Global Diagnosis, Treatment and Pipeline Analysis and Forecast 2013-2020, the global dermatology diagnostics and therapeutics marketwas valued at USD 19.3 Billion in 2015 and is estimated to reach USD 22.5 Billion by 2020, at a CAGR of 3.1% from 2016 to 2020.

Browse the Dermatology Diagnostics and Therapeutics Market – Global Diagnosis, Treatment and Pipeline Analysis and Forecast 2013-2020 at http://www.ihealthcareanalyst.com/report/dermatology-diagnostics-therapeutics-market/    

Diagnosis and treatment of skin abnormalities and diseases covers both medical and surgical aspects dealing with the skin, nails, hair and its diseases along with various topical therapies for specific skin diseases such as dermatitis, warts, and tumors. The dermatology diagnostics and therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for market segmentation based on diagnostic products (dermatoscopes, imaging, microscopes, and trichoscopes), therapeutic products (antibacterial, antifungal, antiviral, biological, corticosteroids, immunosuppressant, and retinoids) and their product pipeline (clinical phase 1, 2 and 3) and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent acquisitions and alliances.

The global dermatology diagnostics and therapeutics market is segmented as:

1.      Diagnostic Product

1.1.    Dermatoscopes

1.2.   Imaging Equipment

1.3.   Microscopes and Trichoscopes

2.     Therapeutic Product (Drug Class)

2.1.   Antibacterials

2.2.  Antifungal Agents

2.3.  Antiviral Agents

2.4.  Biologics

2.5.  Corticosteroids

2.6.  Immunosuppresants

2.7.  Retinoids

3.     Product Pipeline Analysis

3.1.   Phase 1 and Phase 2 Candidates

3.2.  Phase 3 Candidates

3.2.1.      CD5789

3.2.2.     Dupilumab

3.2.3.     IDP-118

3.2.4.     Ixekizumab

3.2.5.     LAS41008

4.     Geography (Region, Country)

4.1.   North America (U.S., Canada)

4.2.  Latin America (Brazil, Mexico, Rest of LA)

4.3.  Europe (U.K., Germany, France, Italy, Spain, Rest of EU)

4.4.  Asia Pacific (Japan, China, India, Rest of APAC)

4.5.  Rest of the World

5.     Company Profiles

5.1.   Agfa-Gevaert N.V.

5.2.  Astellas Pharma, Inc.

5.3.  Cutera, Inc.

5.4.  Dino-Lite Europe/IDCP B.V.

5.5.   Galderma S.A.

5.6.  Genentech (Roche)

5.7.   GlaxoSmithKline -plc (Stiefel Laboratories, Inc.)

5.8.  LEO Pharma A/S

5.9.  Michelson Diagnostics Ltd.

5.10.                    Novartis International AG

5.11.                     Valeant Pharmaceuticals International, Inc.

About Us

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.